NCT05669755进行中（未招募）3 期
The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 7,101
- 试验地点
- 1,179
- 主要终点
- Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
研究概览
简要总结
This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called "placebo") which has no effect on the body. Which treatment participants will get will be decided by chance. Participant's chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 55 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female
- •Age above or equal to 55 years at the time of signing informed consent
- •Body mass index (BMI) greater than or equal to (>=) 25.0 kilograms per meter square (kg/m^2)
- •Established CVD as evidenced by at least one of the following:
- •Prior myocardial infarction
- •Prior stroke (ischemic or haemorrhagic stroke)
- •Symptomatic peripheral arterial disease (PAD) defined as at least one of the following:
- •Intermittent claudication with an ankle-brachial index (ABI) less than (<) 0.85 at rest
- •Intermittent claudication with a >= 50% stenosis in a lower extremity peripheral artery documented by X-ray angiography, magnetic resonance (MR) angiography, computed tomography (CT) angiography or Doppler ultrasound
- •Prior revascularization procedure of a lower extremity peripheral artery
- •Lower extremity amputation at or above ankle due to atherosclerotic disease (excluding e.g., trauma or osteomyelitis)
- •For participants with T2D at screening the following inclusion criteria also apply:
- •Diagnosed with type 2 diabetes mellitus (T2D) >= 180 days before screening
- •HbA1c 6.5%-10% (47-86 millimoles per mole [mmol/mol]) (both inclusive), as measured by central laboratory at screening
- •Treatment with either:
- •Lifestyle intervention alone
- •1-3 marketed oral antidiabetic drugs (OADs) (metformin, α-glucosidase inhibitors (AGI), glinides, sodium-glucose co-transporter 2 inhibitor (SGLT2i), dipeptidyl peptidase 4 (DPP4)-inhibitors, thiazolidinediones, or sulphonylureas (SU) as a single agent or in combination) according to local label
- •Basal insulin alone or in combination with up to two marketed OADs, all according to local label
排除标准
- •Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 60 days before screening
- •Planned coronary, carotid or peripheral artery revascularisation known on the day of screening
- •Heart failure classified as being in New York Heart Association (NYHA) Class IV at screening
- •Treatment with any glucagon-like peptide-1 (GLP-1) receptor agonist (RA) or a medication with GLP-1 activity within 90 days before screening
- •End stage renal disease defined as estimated glomerular filtration rate (eGFR) < 15 millileters per minutes per 1.73^2 (mL/min/1.73 m^2), as measured by the central laboratory at screening
- •Chronic or intermittent haemodialysis or peritoneal dialysis
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive placebo matched to cagrilintide and placebo matched to semaglutide s.c. once weekly for 235 weeks.
干预措施: Placebo (Drug)
CagriSema
Experimental
Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
干预措施: Semaglutide (Drug)
CagriSema
Experimental
Participants will receive cagrilintide and semaglutide subcutaneously (s.c.) once-weekly after a dose escalation period of 16 weeks during the maintenance period of 219 weeks.
干预措施: Cagrilintide (Drug)
结局指标
主要结局
Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke
时间窗: From baseline (week 0) to end of study (up to 242 weeks or more)
Measured in days.
次要结局
- Number of event adjudication committee (EAC)-confirmed malignant neoplasms(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of myocardial infarction (fatal and non-fatal)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of stroke (fatal and non-fatal)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Relative change in body weight(From baseline (week 0) to 120 weeks)
- Change in waist circumference(From baseline (week 0) to 120 weeks)
- Change in systolic blood pressure (SBP)(From baseline (week 0) to 120 weeks)
- Change in diastolic blood pressure (DBP)(From baseline (week 0) to 120 weeks)
- Change in glycated haemoglobin (HbA1c)(From baseline (week 0) to 120 weeks)
- Number of treatment emergent serious adverse events (TESAEs)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Change in waist-to-height ratio(From baseline (week 0) to 120 weeks)
- Change in systolic blood pressure (SBP)(From baseline (week 0) to 120 weeks)
- Time to first occurrence of a composite endpoint: Onset of persistent ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy, Kidney death and CV death(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of composite endpoint consisting of: Onset of persistent macro albuminuria, ≥40% reduction in eGFRcr (CKD-EPI), eGFRcr (CKD-EPI) <15 mL/min/1.73 m^2, Initiation of chronic kidney replacement therapy and kidney death(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of an expanded 5-point MACE composite endpoint consisting of: CV death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularisation and unstable angina requiring hospitalisation(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of a composite endpoint consisting of: all-cause death, non-fatal myocardial infarction and non-fatal stroke(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of myocardial infarction (fatal and non-fatal)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Time to first occurrence of stroke (fatal and non-fatal)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Change in eGFRcr (CKD-EPI)(From baseline (week 0) to 120 weeks)
- Ratio to baseline in Urine albumin-to-creatinine ratio (UACR)(From baseline (week 0) to 120 weeks)
- Relative change in body weight(From baseline (week 0) to 120 weeks)
- Change in waist circumference(From baseline (week 0) to 120 weeks)
- Change in diastolic blood pressure (DBP)(From baseline (week 0) to 120 weeks)
- Ratio to baseline in lipids: Total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, very-low-density lipoprotein (VLDL) cholesterol, triglycerides and free fatty acids(From baseline (week 0) to 120 weeks)
- Change in glycated haemoglobin (HbA1c)(From baseline (week 0) to 120 weeks)
- Number of treatment emergent serious adverse events (TESAEs)(From baseline (week 0) to end of study (up to 242 weeks or more))
- Number of event adjudication committee (EAC)-confirmed malignant neoplasms(From baseline (week 0) to end of study (up to 242 weeks or more))
- Number of severe hypoglycaemic episodes (level 3) (only for participants with type 2 diabetes mellitus [T2D] at screening)(From baseline (week 0) to end of study (up to 242 weeks or more))
研究者
研究点 (1179)
Loading locations...
相似试验
进行中（未招募）
1 期
A research study to see the effects of CagriSema in people living with diseases in the heart and blood vesselsAtherosclerotic cardiovascular diseaseMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-005855-35-DEovo Nordisk A/S7,000
进行中（未招募）
1 期
REDEFINE 3: A research study to see the effects of CagriSema in people living with diseases in the heart and blood vesselsCardiovascular diseaseCTIS2023-506924-94-00ovo Nordisk A/S5,054
招募中
1 期
A research study to see the effects of CagriSema in people living withdiseases in the heart and blood vesselsAtherosclerotic cardiovascular diseaseMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-005855-35-PLovo Nordisk A/S7,000
进行中（未招募）
1 期
A research study to see the effects of CagriSema in people living with diseases in the heart and blood vesselsAtherosclerotic cardiovascular diseaseMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-005855-35-BGovo Nordisk A/S7,000
进行中（未招募）
1 期
A research study to see the effects of CagriSema in people living with diseases in the heart and blood vesselsAtherosclerotic cardiovascular diseaseMedDRA version: 26.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 10047065 - Vascular disordersEUCTR2021-005855-35-DKovo Nordisk A/S7,000